Sofosbuvir/velpatasvir/voxilaprevir
Combination of | |
---|---|
Sofosbuvir | NS5B RNA polymerase inhibitor |
Velpatasvir | NS5A inhibitor |
Voxilaprevir | NS3/4A protease inhibitor |
Clinical data | |
Trade names | Vosevi |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617037 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
JSmol) | |
| |
|
Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a
fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.[1] Vosevi was approved for medical use in the United States and in the European Union in July 2017.[2][3] Vosevi is sold by Gilead Sciences.[citation needed
]
References
- PMID 31413603.
- ^ "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.
- ^ "Vosevi EPAR". European Medicines Agency (EMA). Retrieved 24 September 2020.